WELL LEAD MEDICAL CO LTD Class A

WELL LEAD MEDICAL CO LTD Class A

SSSE:603309
10.95
CNY
+0.02
(+0.18%)
0.16EPS
98.33P/E
3.26BMarket Cap
Apr 16Next Earn

Total Valuation

CNY

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A carries a market capitalization of 3.26B, placing it among publicly traded companies globally. Its enterprise value stands at 3.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.26B
Enterprise Value3.38B

Important Dates

WELL LEAD MEDICAL CO LTD Class A's next confirmed earnings release is scheduled for April 16, 2027.

Earnings Date4/16/2027

Share Statistics

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A has 291.87M shares outstanding.

Shares Outstanding291.87M

Valuation Ratios

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A trades at a trailing price-to-earnings ratio of 98.33. The price-to-sales ratio is 1.96, and the price-to-book ratio stands at 1.79.

PE Ratio98.33
PS Ratio1.96
PB Ratio1.79
P/TBV Ratio2.15

Enterprise Valuation

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A trades at an EV/EBITDA multiple of 40.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 40.21 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.38B versus a market cap of 3.26B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.04
EV / EBITDA40.21
EV / EBIT40.21

Financial Position

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.46, indicating elevated leverage, while an interest coverage ratio of 5.08 demonstrates adequate ability to service its debt obligations.

Current Ratio1.78
Quick Ratio0.92
Debt / Equity32.46
Debt / EBITDA7.11
Interest Coverage5.08

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 581,832.42 in revenue per employee across its workforce of 2,849.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee581,832.42
Employee Count2,849.00

Taxes

CNY

Over the twelve months ended September 30, 2026, WELL LEAD MEDICAL CO LTD Class A recorded 37.33M in income tax expense. That works out to an effective tax rate of 45.02, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 82.93M, leaving 33.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax37.33M
Effective Tax Rate45.02

Stock Price Statistics

CNY

As of the close on November 17, 2026, WELL LEAD MEDICAL CO LTD Class A's stock has declined approximately 22.17% over the past 52 weeks. The 50-day moving average sits at 10.97, while the 200-day moving average is 12.66.

52-Week Price Change-22.17%
50-Day Moving Average10.97
200-Day Moving Average12.66

Income Statement

CNY

Over the twelve months ended September 30, 2026, WELL LEAD MEDICAL CO LTD Class A generated 1.66B in revenue and converted that into 33.00M in net income, yielding earnings per share of 0.16. EBITDA reached 84.16M, while operating income came in at 273.43M.

Revenue1.66B
Gross Profit715.66M
Operating Income273.43M
Pretax Income82.93M
Net Income33.00M
EBITDA84.16M
EBIT84.16M
Earnings Per Share (EPS)0.16

Balance Sheet

CNY

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A holds 493.55M in cash and equivalents against 598.05M in total debt, resulting in a net debt position of 233.77M. Total book value stands at 1.83B, with working capital of 416.70M providing operational flexibility.

Cash & Cash Equivalents493.55M
Total Debt598.05M
Net Debt233.77M
Equity (Book Value)1.83B
Book Value Per Share6.26
Working Capital416.70M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-168.20M

Margins

Over the twelve months ended September 30, 2026, WELL LEAD MEDICAL CO LTD Class A posted a gross margin of 43.17, reflecting its pricing power and cost economics. The operating margin of 16.49 and net profit margin of 1.99 provide insight into operational efficiency.

Gross Margin43.17
Operating Margin16.49
Pretax Margin5.00
Profit Margin1.99
EBITDA Margin5.08

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, WELL LEAD MEDICAL CO LTD Class A paid dividends of 0.54 per share. The dividend payout ratio of 270.03 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to WELL LEAD MEDICAL CO LTD Class A shareholders.

Dividend Per Share0.54
Payout Ratio270.03
Shareholder Yield5.59

Stock Splits

WELL LEAD MEDICAL CO LTD Class A's most recent stock split took place on May 25, 2020 with a 10:13 split ratio.

Last Split Date5/25/2020
Split Ratio10:13

Scores

As of September 30, 2026, WELL LEAD MEDICAL CO LTD Class A has an Altman Z-Score of 3.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.64